U.S. Markets closed
  • S&P Futures

    3,411.75
    -20.75 (-0.60%)
     
  • Dow Futures

    27,971.00
    -163.00 (-0.58%)
     
  • Nasdaq Futures

    11,624.25
    -67.00 (-0.57%)
     
  • Russell 2000 Futures

    1,594.80
    -8.30 (-0.52%)
     
  • Crude Oil

    39.79
    -0.24 (-0.60%)
     
  • Gold

    1,918.60
    -10.90 (-0.56%)
     
  • Silver

    24.93
    -0.31 (-1.23%)
     
  • EUR/USD

    1.1844
    -0.0022 (-0.1895%)
     
  • 10-Yr Bond

    0.8160
    +0.0190 (+2.38%)
     
  • Vix

    28.65
    -0.70 (-2.39%)
     
  • GBP/USD

    1.3131
    -0.0012 (-0.0945%)
     
  • USD/JPY

    104.6970
    +0.1370 (+0.1310%)
     
  • BTC-USD

    12,841.21
    +1,784.20 (+16.14%)
     
  • CMC Crypto 200

    257.29
    +12.40 (+5.06%)
     
  • FTSE 100

    5,776.50
    -112.72 (-1.91%)
     
  • Nikkei 225

    23,481.45
    -85.55 (-0.36%)
     

Company News For Jan 29, 2020

Zacks Equity Research
·1 min read
  • Shares of Armata Pharmaceuticals, Inc. ARMP surged 77.1% after the company along with Innoviva, reported a $25 million strategic investment to support the progress of Armata's bacteriophage development programs.

  • Shares of Ocean Bio-Chem, Inc. OBCI gained 18.8% after the company's subsidiary, Star Brite, announced its product PERFORMACIDE is registered with EPA as a virucide against the coronavirus.

  • Shares of Graco Inc. GGG rose 7.1% after the company reported quarterly earnings of 48 cents per share, which surpassed the Zacks Consensus Estimate of 39 cents.

  • Shares of 3M Company MMM declined 5.7% after the company’s quarterly earnings of $1.95 per share missed the Zacks Consensus Estimate of $2.10.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
3M Company (MMM) : Free Stock Analysis Report
 
Graco Inc. (GGG) : Free Stock Analysis Report
 
AmpliPhi Biosciences Corporation (ARMP) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research